RS Oncology

Executive Summary

RS Oncology is a clinical-stage biotechnology company developing first-in-class small molecule therapies targeting the mitochondrial protein PRX3 to treat oxidative-stress-dependent cancers. Founded in 2018 and based in Cambridge, USA, the company's lead candidate, RSO-021, is designed to selectively kill cancer cells by disrupting their antioxidant defense systems. The company is currently in Phase 2 clinical development, leveraging a novel mechanism that exploits vulnerabilities in cancer cell metabolism. RS Oncology's approach addresses a significant unmet need in oncology, particularly in tumors resistant to standard therapies due to high oxidative stress.

Upcoming Catalysts (preview)

• H2 2026Phase 2 interim data readout for RSO-02180% success
• H2 2026Strategic partnership or licensing deal for RSO-02130% success
• H1 2027IND submission for second-generation PRX3 inhibitor or new indication50% success